

Product Datasheet

PI 828

Catalog No. **BP-01363** · CAS **942289-87-4** · Form **free base** · Physical state **solid** · Color **white to yellow** · Version **1.0** ·
 Revision **2026-09-04**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target PI3K; Casein Kinase	Research area Cancer
--------------------------------------	--------------------------------

Molecular formula **C₁₉H₁₈N₂O₃**

Molecular weight **322.3578**

STRUCTURE



DESCRIPTION

PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid kinase assay, respectively.

BIOLOGICAL ACTIVITY

In Vitro

PI-828 (0.01-100 μM) exhibits cytotoxic effect on the 4T1 breast cancer cells and 4306 ovarian cancer cells.

PI-828 (0.78-3.12 μM; 48 hours) decreases caspase 3 activation; higher concentrations of PI-828 (6.25-12.5 μM) alone causes apoptosis.

SOLUBILITY

soluble in DMSO

REFERENCES

- [1]. Gharbi SI, et al. Exploring the specificity of the PI3K family inhibitor LY294002. *Biochem J.* 2007 May 15;404(1):15-21.
- [2]. Kulkarni AA, et al. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. *Cancer Res.* 2013 Dec 1;73(23):6987-97.
- [3]. Zellefrow CD, et al. Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay. *Radiat Res.* 2012 Sep;178(3):150-9.